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1  ZUSAMMENFASSUNG 
 
Hintergrund 
Ziel der Untersuchung war es die Sicherheit und Funktion des neuen Protégé Stents 
bei der Behandlung von Stenosen der Arteria Carotis communis und der Arteria 
Carotis interna zu evaluieren. 
Methodik 
Der Protégé GPS Stent ist ein selbst-expandierender Nitinol Stent. Er ist montiert auf 
einem 6 Fr (6-9mm Stent) oder 7 Fr (10mm Stent) Over-the-Wire-Deliverysystem und 
besitzt ein neuartiges Stentfreisetzungssystem um eine exakte Plazierung zu 
ermöglichen.  
77 Patienten wurden in die Studie eingeschlossen. Die Patienten wurden vor dem 
Eingriff, während des Eingriffs, vor Entlassung, nach einem und nach sechs Monaten 
klinisch und mittels Duplexsonographie untersucht.  
Ergebnisse 
Siebenundsiebzig Stenosen wurden behandelt. 31 Stenosen waren symptomatisch, 46 
asymptomatisch. Der Eingriff war technisch  erfolgreich bei 76 (99%) Patienten. Der 
Stenosegrad wurde von 86 ± 7 % auf  16 ± 8 % reduziert. In einem Fall war der 
Eingriff erfolglos, da das Embolieprotektionssystem nicht zurückgezogen werden 
konnte und infolgedessen operativ entfernt werden musste. Innerhalb der ersten 30 
Tage ereigneten sich  4 (5,2%) Major Adverse Neurological Events (MANEs). Drei 
der MANEs waren Major Strokes (3,9%), 1 Minor Stroke. Das fünfte MANE 
ereignete sich vor der 6-Monatsuntersuchung; dieser Patient hatte einen Major Stroke 
am Tag 75 nach dem Eingriff und verstarb 36 Tage später. Ein weiterer Patient 
verstarb an einer Urosepsis.  
Schlussfolgerung 
Die Untersuchungen haben gezeigt, dass der Protégé Stent die Sicherheits- und 
Funktionskriterien der Behandlung von Stenosen der Arteria Carotis interna erfüllt.   - 6 -
Die Komplikationsrate war vergleichbar mit derjenigen in anderen Carotis Stent- 
sowie Carotis Endarterektomie Studien.   - 7 -
2  ABSTRACT 
 
Background 
The purpose of the trial was to evaluate the safety and performance of the new Protégé 
stent in the treatment of common and/or internal carotid artery stenoses.  
Methods 
The Protégé® GPS stent is a self-expanding Nitinol stent system.  It is mounted on a 6 
Fr 0.018” (6-9mm stent) or 7 Fr, 0.035” (10mm stent) over-the-wire-delivery system 
and includes a new stent release system which allows exact placement of the stent.  
Seventyseven patients were enrolled in the trial. Study patient assessments were 
conducted clinically and by duplex scan at baseline, peri-procedure, discharge, one and 
six months post procedure.  
Results 
Seventyseven lesions were treated. Thirtyone lesions were symptomatic, 46 lesions 
were asymptomatic. The procedure was technically successful in 76 (99%) lesions. 
The percentage of stenosis was reduced from 86 ± 7 % to  16 ± 8 %.  One procedure 
failed because the embolic protection device could not be retrieved and the patient was 
sent to surgery. Within 30 days there were 4 (5.2%) Major Adverse Neurological 
Events (MANEs). Three of the MANEs were major strokes (3.9%), one a minor 
stroke. The fifth MANE occurred prior to the six month follow-up visit; this patient 
had a major stroke 75 days after the procedure and died 36 days later. One additional 
death occurred due to urosepsis. 
Conclusions 
The trial shows that the Protégé stent satisfies safety and performance criteria for the 
treatment of carotid artery stenosis. The complication rate was comparable to the 
incidence of these events in other recent carotid stent and endarterectomy studies.    - 8 -
3  INTRODUCTION 
 
3.1  Natural History of Carotid Disease 
In the aging population, stroke is the most common and disabling neurological 
disorder, with more than half a million annual strokes in the United States alone. It is 
the third most common cause of death on industrial nations. There are approximately 
one million stroke-related events each year, including 500,000 new strokes, 200,000 
recurrent strokes, and 240,000 TIAs. On average, someone has a stroke every 45 s and 
someone dies of stroke every three minutes [1] 
 
Ischemic events are the cause of the vast majority of strokes (80 to 85%). 
Epidemiological trials have shown that ischemic events occur approximately four 
times as often as intracerebral bleeding [2]. It is known that the incidence of ischemic 
strokes significantly increases with age (33% in patients under 45 years of age and 
80% in patients over 50 years of age). Of these, almost one third of all ischemic 
strokes are caused by carotid artery disease. More than 80% of clinical symptoms are 
due to embolism originating from arteriosclerotic plaques in carotid artery stenoses. In 
approximately 20% the strokes occur because of hemodynamic impairment of the 
cerebral circulation. The pattern of progression of carotid stenosis has shown to be 
unpredictable as the disease may progress swiftly or slowly, or remain stable for many 
years. [3, 4] 
 
3.2  Morphology and Pathophysiology  
Atherosclerotic disease is known to be a systemic disease. In most cases it not limited 
to a singular vascular bed, but instead affects all arteries throughout the body. Patients 
who suffer from symptomatic atherosclerosis in one vascular bed, for example patients 
with coronary heart disease are not only at risk of myocardial infarction, but are also at   - 9 -
risk of atherosclerotic disease of supraaortal and cerebral arteries leading to stroke, as 
well as atherosclerotic disease of peripheral arteries leading to limb ischemia.  
 
Although atherosclerosis is the most common disease of the carotid arteries, it is 
important to be aware of further conditions associated to cerebral ischemia and 
infarction. These conditions include diseases of the aorta (dissection, aneurysm, 
aortitis), arteritis, fibromuscular dysplasia, dissection, dolichoectasia, primary vascular 
tumors, trauma, and complications of neck and head tumors.  
 
Carotid atherosclerosis can produce retinal and cerebral symptoms by one of two 
major mechanisms, including progressive carotid stenosis leading to in-situ occlusion 
and hypoperfusion, or intracranial arterial occlusion resulting from embolization. 
Patients with carotid stenosis may develop symptomatic cerebral hypoperfusion from 
systemic causes. Patients in whom carotid distribution cerebral ischemia is suspected, 
should be closely evaluated for treatable causes, including sources of thrombogenic 
emboli from the carotid arteries, heart, and aortic arch [5]. 
 
The degree of carotid stenosis is associated with the risk of suffering stroke. Carotid 
stenoses greater than or equal to 50% have been identified in 7% of men and 5% of 
women older than 65 years. If there is slow flow through a severe stenosis a bruit may 
be absent. Therefore, cervical bruits are neither specific nor sensitive for identifying 
severe carotid artery disease. The risk of progression of carotid stenosis is 9.3% per 
year. Risk factors for progression include ipsilateral or contralateral ICA stenosis 
greater than 50%, ipsilateral ECA stenosis greater than 50%, and systolic blood 
pressure greater than 160 mm Hg. The annual stroke risk in patients with carotid 
stenosis is most dependent on the patient´s symptom status and stenosis severity. 
However, it is also influenced by the presence of silent cerebral infarction, 
contralateral carotid disease, extent of collaterals, the presence of atherosclerotic risk 
factors, plaque morphology, and other clinical features as well. [5, 6, 7]   - 10 -
Atherosclerotic disease in the internal carotid artery begins as thinkening of the vessel 
wall. When the intima-media complex is measured >1 mm the term plaque is used.  
Significant narrowing of the internal carotid artery or plaque rupture may lead to an 
ischemic occlusion of cerebral arteries. In cases of unstable atherosclerotic lesions, 
thrombus formations can be released, which then result in cerebral embolism. These 
situations mostly result in a stroke. In 2004, Biasi et al reported on the index of 
echogenicity, named the grey-scale median as a risk indicator of stroke during carotid 
stenting. [8] They concluded that carotid plaque echolucency, as measured by grey-
scale median  ≤25, increases the risk of stroke in carotid artery stenting. 
 
3.3  Neurovascular Anatomy  
Knowledge of the extra- and intracerebral anatomy is fundamental. The left common 
carotid artery arises from the aortic arch, while the right arises from the bifurcation of 
the brahiocephalic trunk. Neither common carotid artery has side branches, but each 
divides into the internal and external carotid artery at the level of the upper boarder of 
the thyroid cartilage. The external carotid artery starts at the bifurcation of the 
common carotid artery supplying the jaw, face, neck and meninges. The two terminal 
branches of the external carotid artery are the superficial temporal artery and maxillary 
artery. These two branches in addition to the occipital artery can serve as collateral 
channels for blood supply to the brain if the internal carotid artery or the vertebral 
artery is occluded. Vertebral arteries provide the brain with only a small amount of 
blood but can become more important if the carotid arteries are narrowed or blocked. 
The internal carotid artery ascends laterally behind the hypopharynx where it can be 
palpated. It bifurcates into the anterior cerebral artery and the larger middle cerebral 
artery. The extracranial segment of the internal carotid artery does not have significant 
branches visible. The first major intracranial branch is the ophthalmic artery. 
 
In young adults and children the aortic arch is symmetrically curved and the origins of 
the brachiocephalic arteries are aligned in straight lines and courses superiorly. [9] The 
aging and arteriosclerotic process elongate and distend the aortic arch. The ostia of the   - 11 -
brachiocephalic arteries are shifted - the Aortic knob becomes more superior and 
posterior. It becomes more difficult to selectively catheterize these vessels. 
Furthermore, the internal carotid arteries themselves develop tortuosities during the 
aging process. This has to be considered during the intervention, as it can make the 
cannulation of the artery as well as filter and stent placement very challenging. 
 
The most important intracranial collateral pathway is the circle of Willis, connecting 
through the anterior and posterior communicating arteries the anterior, middle and 
posterior cerebral arteries. In situations where the atherosclerotic process develops 
gradually, this circle can compensate an occluded internal carotid artery. Yet it is 
essential to know that the circle of Willis is not complete in all patients. In these 
patients, even a short, temporary occlusion of the internal carotid artery can result in a 
disabling stroke. 
 
3.4 Historical  Perspective  of Carotid Endarterectomy (CEA) 
The intention of interventional or surgical treatment of the carotid artery is focused on 
removing debris that is likely to cause distal embolisation or a hemodynamic 
significant vessel lumen narrowing.   
 
Surgical treatment for carotid artery stenosis is the traditional standard of care, initially 
performed in the 1950's by pioneers such as DeBakey, Eascott, and Cooley [10, 11]. 
Initial surgical trials were prematurely stopped due to high morbidity and mortality 
rates [12, 13, 14]. By the early 1980s, Carotid endarterectomy was the most frequently 
performed vascular surgical procedure. However, the failure of the external carotid–
internal carotid bypass operation to prevent stroke and the absence of clinical trial data 
provoked challenges about the safety and efficacy of CEA [15, 16].. Only in the 
nineties randomized trials could prove benefit of carotid endarterectomy compared to 
medical treatment. One of these trials, the NASCET Trial [17, 18], demonstrated a 30 
day death and stroke rate of 5.8% in patients with severe stenosis of more than 70%.   - 12 -
This rate increased to only 6.7% at eight years of follow up. However, the only high- 
risk group included was patients with contralateral occlusion. A sub- analysis of this 
patient group showed a higher combined stroke and death rate of 14%. On the other 
hand, it was shown that patients with stenoses of less than 50% did not benefit from 
surgery [19].     
 
The results found in the ECST Trial could also confirm the superiority of CEA 
compared to medical therapy. The perioperative stroke and death rate was 7.5% in the 
surgical arm. CEA could further reduce the 3 year rate of stroke and death to 14.9% 
compared to medical therapy with 26.5% [20].  
 
3.5 Potential  Complications  of Carotid Endarterectomy 
Potential complications after CEA include cardiovascular complications (vasovagal 
andvasodepressor reaction, myocardial infarction), neurological complications (stroke, 
hyperperfusion syndrome, intracranial hemorrhage, seizures, cranial nerve injury), 
wound problems (infection, hematoma), injury to the carotid artery (dissection, 
thrombosis, restenosis), and death.  
 
3.6  Historical Perspective of Carotid Stenting 
In the past several years, carotid stenting has rapidly developed into an alternative to 
surgery and is increasingly the preferred method in surgically high-risk patients [21, 
22, 23, 24]. Many patients tend to favor stenting to surgery, because it is less invasive, 
does not cause a scar and requires only a short hospital stay less than 24 hours. Other 
advantages of the interventional approach over carotid surgery include the ability to 
diagnose and treat embolic complications immediately. Furthermore, the fact that the 
patient can be awake during the procedure, allows close neurological monitoring. 
Complications like distal embolization can therefore be recognized and treated 
immediately. 
   - 13 -
Three randomized trials (Brooks Trial [14], CAVATAS [23] and SAPPHIRE [24]) 
showed equivalency of carotid angioplasty/stenting and CEA at least in selected 
patients.  
 
3.7  Potential Benefits of Carotid Stenting 
If the results are similar, patients may prefer angioplasty and stent implantation 
because it is less invasive than surgery, does not cause a scar and requires a short 
hospital stay. It provides the ability to immediately diagnose and treat embolic 
complications, and the patient can be awake, allowing close neurological monitoring.  
 
3.8  Embolic Protection Devices 
A major limitation of carotid angioplasty is peri-interventional distal embolisation. 
Balloon dilatation, stenting and manipulation of the vessels through catheters and 
wires are likely to release debris that can cause severe cerebral damage. Therefore, in 
most centers embolic protection devices are used routinely. Currently, there are three 
different approaches to cerebral protection: Filters, distal occlusion balloons and 
proximal occlusion balloons which occlude the common and external carotid artery.  
 
3.8.1  Types of Embolic Protection Devices 
3.8.1.1  Distal Occlusion Balloons 
Distal occlusion balloons were the first system of protection commercially available 
and therefore used on a large scale.  They consist of a 0.014 inch guide with a balloon 
mounted on the distal portion that is inflated and deflated through a very small channel 
contained in the guide itself (Guardwire® Temporary Occlusion and Aspiration 
System (Medtronic Vascular), TriActiv® ProGuard™ Embolic Protection System 
(Kensey Nash). The lesion is crossed with the guide thereby positioning the balloon 
distally to the stenosis where it is inflated until the blood flow in the internal carotid 
artery is blocked. Following this, the angioplasty and stenting procedure is carried out.   - 14 -
On completion of the procedure, a catheter is advanced up to the distal balloon and the 
column of blood contained in the occluded internal carotid artery is aspirated. In this 
way debris dislodged during the stent procedure can be eliminated. Afterwards the 
balloon is deflated and the guide is removed. The advantages of distal occlusion 
balloons are their small diameter (2.2 French), their good maneuverability and 
flexibility. Possible disadvantages are that internal carotid artery occlusion is not 
tolerated by 6–10% of patients [25, 26] and that it is not possible to image the vessel 
distal to the occlusion balloon with contrast medium during inflation. 
 
3.8.1.2 Filter  Devices 
Most filters consist of a metallic structure coated by a membrane of polyethylene or a 
Nitinol net containing holes of 80–200 μm in diameter. The filters are usually 
positioned at the distal portion of a 0.014 inch guide. During the procedure the filters 
are enclosed into a delivery catheter with which they are advanced distal to the 
stenosis. After the lesion is crossed, the filter is opened by removing the delivery 
sheath. At the end of the stenting procedure, the filter is closed into the distal tip of a 
retrieval catheter and removed from the carotid artery.  
A large  number of second or third generation filters are currently available. The 
technical characteristics of a good filter consist of a low profile (< 3 French), an 
adequate torqueability to cross tortuous vessels and, when opened, an adequate 
apposition to the wall to assure the best possible embolic protection.  
 
The FiberNet device is the first embolic protection device which combines features of 
a filter and of a distal occlusion device in one system. It consists of a 3-dimensional 
Polyethylene Terephthalate (PET) fiber-based filter which has the ability to capture 
particles as small as 40ų, mounted onto a 0.014 inch, 190 cm wire and focal suction is 
provided through a retrieval catheter. 
 
   - 15 -
3.8.1.3  Distal Occlusion Balloons 
Distal protection devices, both occlusive balloons and filters, have the disadvantage 
that it is mandatory to cross the lesion before they are inflated or opened. This 
unavoidable step carries the risk of embolisation during this ‘unprotected’ phase of the 
procedure. Proximal protection systems such as the Gore Neuro Protection System 
(Gore) and MO.MA system (Invatec), provide cerebral protection before passing any 
type of device through the stenosis. This is especially important in lesions which 
contain fresh thrombus. The operator can use the wire of his choice which helps to 
cross difficult lesions. These systems consist of a long introducer sheath with a balloon 
that is inflated in the common carotid artery. A second balloon, inflated in the external 
carotid artery, assures the total blockade of the antegrade blood flow in the internal 
carotid artery. The proximal protection systems facilitate the cerebral vascular 
connections of the circle of Willis. After the occlusion of the common and external 
carotid artery, the collateral flow through the circle of Willis creates so-called ‘back-
pressure’ which prevents antegrade flow in the internal carotid artery. After stent 
positioning, and before deflation of the balloons in the common and external carotid 
artery, the blood in the internal carotid artery – possibly containing dislodged debris – 
is aspirated and removed. Intolerance of balloon occlusion seen in some patients is an 
ongoing disadvantage of proximal protection systems [27].  
 
3.9  The PROCAR Trial: Protégé Stent in the Treatment of Carotid Artery Stenosis 
with Adjunctive Use of a Filter Embolic Protection Device 
A prospective, multicenter trial was conducted to assess the safety and performance of 
the Protégé GPS stent (ev3, Inc) in the treatment of de novo or restenotic common 
and/or internal carotid artery stenoses with adjuvant use of a filter embolic protection 
device.  
 
The Protégé GPS stent is a self-expanding Nitinol stent developed for the treatment of 
carotid artery stenosis which includes a new stent release system which allows exact   - 16 -
placement of the stent. The delivery system is comprised of an inner and outer sheath, 
which are locked together with a safety lock. Stent positioning at the targeted lesion is 
achieved prior to deployment using the two radiopaque markers on the inner sheath, 
which mark the location of the constrained stent. For stent deployment, the safety lock 
is turned counterclockwise to unlock the outer sheath.  The outer sheath retraction is 
achieved by pulling the distal grip toward the proximal grip. Complete deployment of 
the stent is achieved when the radiopaque marker on the outer sheath is just proximal 
to the proximal marker on the inner sheath. This ensures that the stent is held in place 
until the stent is fully released to prevent the stent from jumping forward during 
deployment.    - 17 -
4  METHODS 
4.1  Study Design and Objectives 
The trial was designed to evaluate the safety and performance of the Protégé Stent in 
the treatment of common and/or internal carotid artery stenosis with adjunctive use of 
a filter embolic protection device. Operators were free to choose any distal embolic 
protection device of their choice. Patients in whom the Protégé Stent could not be 
placed were followed in the trial through hospital discharge (intention to treat 
analysis). The primary endpoint was the incidence of device or procedure-related 
major adverse neurological events (MANE) through one month, assessed by an 
independent neurologist. MANE was defined as any major or minor stroke, and all 
death. The distinction between major and minor stroke was made by use of the NIH 
Stroke Scale (Figure 1). Secondary endpoints addressed safety and performance of the 
Protégé Stent and included the following: (1) Technical success: Ability to perform 
Protégé Stent placement with adjunctive use of a filter embolic protection device with 
residual stenosis < 30%, (2) correct placement of the Protégé Stent, (3) primary 
patency of the treated vessel as determined by duplex scan at one and six months and 
(4) incidence of device or procedure-related MANE at discharge and six months. The 
overall study design is shown in Figure 1. 
 
Figure 1: Stroke Classification 
 
Major Stroke  Classification 
NIH >  15  If NIH >4 at enrolment, any change >5 
points is a major stroke post procedure 
Minor Stroke  Classification 
NIH < 4  If NIH > 4 at enrolment, any change < 4 
points is a minor stroke post procedure   - 18 -
4.2  Study Requirements 
The selection criteria are listed in figure 2 and 3. Informed consent was obtained in 
accordance with Ethics Committee policies, procedures and regulations. The initial 
screening was undertaken by performing a physical examination, which included a 
medical history, a complete neurological examination including NIH Stroke Scale, 
routine clinical laboratory tests, perfusion/diffusion brain CT scan or MRI and a 
carotid duplex scan. The procedural angiographic measurement was the final 
determinant of eligibility (≥80% stenosis for asymptomatic patients, ≥70% stenosis for 
symptomatic patients). The severity of stenosis was measured using the North 
American Symptomatic Carotid Endarterectomy Trial (NASCET) method. Successful 
placement of the filter embolic protection device was mandatory for inclusion in the 
study. The overall study design is shown in figure 4. 
   - 19 -
Figure 2: Inclusion Criteria 
•  De novo or restenotic lesion located in the common and/or internal carotid 
artery and suitable for PTA/stenting with adjunctive use of a filter embolic 
protection device 
•  Target lesion stenosis is defined according to angiographic NASCET criteria 
•  >80% stenosis for asymptomatic patients 
•  ≥70% stenosis for symptomatic patients 
•  Symptomatic patients are defined as those with carotid stenosis associated with 
ipsilateral cerebral or visual transient ischemic attack (TIA) evidenced by 
amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral ischemic stroke 
within 6 months prior to enrollment 
•  Filter embolic protection device is successfully placed. 
•  Patient is a candidate for femoral access percutaneous interventional treatment 
of a carotid lesion with stenting 
•  Reference vessel diameter for stent placement is > 4.5 and < 9.5 mm 
•  Vessel diameter distal to target lesion allows placement of a filter embolic 
protection device 
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Figure 3: Exclusion Criteria 
•  Planned to treat another vessel in the same procedure 
•  Life expectancy of less than six months 
•  Abnormal International Ratio (INR) level (<1.5 or >3.5) while on 
coumadine/warfarin treatment 
•  Intolerance to heparin, or aspirin, or clopidogrel and ticlopidine 
•  Allergy to nickel or titanium 
•  Myocardial infarction (MI) within 3 days prior to the procedure 
•  Acute stroke or stroke in evolution within 14 days prior to the procedure 
•  Major residual neurological deficit (stroke scales:  NIH >15 at pre-procedure 
neurological exam 
•  Ipsilateral intracranial stenosis more severe than target lesion stenosis 
•  Total occlusion of target vessel 
•  Target lesion is in an in-stent restenosis 
•  Presence of multiple carotid stenoses in the same vessel that can not be covered 
by two overlapping Protégé stents 
•  Presence of intracranial tumor(s), arterial vascular malformations (AVMs), or 
aneurysms 
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Figure 4: Overall Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does patient meet angiographic criteria? 
Is the filter embolic protection device deployed?  NO  Do not enroll 
NO  Do not enroll 
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4.3  Outcome Analysis 
To control inter-observer variability, the author determined the angiographic and 
duplex results of all study patients included in the data analyses and was contiuously 
supervised by an independent angiographic and duplex core laboratory (Heart Core, 
Leiden, The Netherlands) . Although each investigator's visual assessment was used to 
determine patient eligibility at the time of enrolment, the author´s values superseded 
the investigator's measurements. 
 
An independent Clinical Event Committee (CEC) adjudicated all reported 
complications to classify them as MANEs according to the definitions as outlined in 
the protocol.  
 
The statistical analysis of the patient population was based on the principle of 
intention-to-treat. The analysis population consisted of all patients who gave informed 
consent, fit the selection criteria and in whom a carotid procedure was attempted. All 
analyses were conducted using SAS Version 8.   
 
The primary performance parameter was the incidence of device or procedure MANEs 
during the procedure through one month. The incidence of all MANEs and each type 
of MANE was calculated by dividing the number of patients with a MANE by the 
number of patients treated. The 95% confidence limits on the rate were also calculated. 
Product-limit estimates of the survival and occurrence rates (with 95% confidence 
limits) at one month (31 days post-procedure) and six months (180 days post-
procedure) were also calculated. 
Secondary performance endpoints included: 
•  Ability to perform Protégé Stent placement with adjunctive use of a filter 
embolic protection device with residual stenosis < 30%   - 23 -
•  Primary patency as determined by Duplex Scan at one and six months 
•  Incidence of device or procedure related MANEs at discharge and six months 
 
Successful placement of the stent was analyzed descriptively, by calculating the 
numbers and percentages of patients in whom no difficulties were experienced. 
Residual stenosis was summarized by calculating the minimum and maximum values 
and the numbers and percentages of patients with none, 1-10%, 11-20% and >20% 
residual stenosis. Primary patency was evaluated by calculating the number and 
percentage of patients with re-stenosis at one month.  
 
4.4  Procedure Management 
Patients were pre-treated with a minimum of 100 mg aspirin p.o. within 1 hour prior to 
the procedure and clopidogrel (e.g. Plavix®) 300 mg p.o. within 24 hours prior to 
procedure, but no later than 2 hours before the start of the procedure. In case of 
intolerance to clopidogrel, 500 mg ticlopidine could be used as an alternative.  
 
Percutaneous femoral artery access was secured via standard sterile technique. 
Sufficient heparin was administered to maintain the activated clotting time ≥ 250 
seconds throughout the interventional portion of the procedure. Angiography of the 
carotid artery was performed to identify the anatomical characteristics of the 
intracranial and carotid vessels and to provide information on the lesion. Based on the 
NASCET method, calculations were performed to determine the degree (percent), 
length of the stenosis and sizing requirements for the filter embolic protection device. 
Intracranial circulation films were obtained immediately prior to and after the 
implantation procedure to document baseline and final results. Any of the available 
filter embolic protection device could be used. If the filter embolic protection device 
was removed during the procedure and the investigator continued to perform 
additional PTA and/or stenting of the lesion, a new filter embolic protection device   - 24 -
had to be selected and placed in the artery before continuing the procedure. Carotid 
artery angioplasty and stenting was performed using standard angioplasty methods and 
equipment as described below [28]. 
•  Femoral/Transbrachial/Radial Access:  
Puncture of the artery with a Seldinger needle, placement of a 5-6 French 12 cm 
arterial sheath or cut-down (brachial artery). 
 
•  Cannulation of the Common Carotid Artery:  
5F diagnostic catheter is advanced over a 0.035” guide wire into  the ascending 
aorta. 
 
•  Carotid Sheath/Guiding Catheter Placement:  
Cannulation of the external carotid artery, removal of the diagnostic catheter, 
placement of a long carotid sheath in the common carotid artery or placement of a 
guiding catheter (in this case no diagnostic catheter is previously needed). 
 
•  Pre-dilatation:  
Usually a 3-4 mm balloon is chosen. Pre.dilatation is only performed if degree of 
stenosis or severe calcification prevents direct stenting. 
 
•  Placement of Embolic Protection Device: 
Distal filters are placed in a straight vessel segment approximately 2 cm distal to 
the lesion. Distal occlusion balloon are placed and inflated in the pars petrosa of 
the internal carotid artery. Proximal occlusion systems are placed and inflated in 
the common external and common carotid artery. 
 
•  Stent Deployment:   - 25 -
The diameter of the self-expanding stent should be 1-2 mm larger than the widest 
diameter to be covered. The length of the stent should cover the entire lesion. 
 
•  Post-dilatation:  
The balloon should be placed in the stent-segment placed in the internal carotid 
artery. The diameter of the balloon should be equal to the diameter of the internal 
carotid artery distal to the stent (usually 5-6 mm in diameter). To prevent 
dissections, post-dilation should be performed at nominal pressure. 
 
Post-stent deployment dilation(s) was left to the discretion of the investigator and 
could be performed with an appropriately sized, low-compliance balloon catheter to 
ensure that the stent was in full contact with the arterial wall. Peri-stent dissections 
could be treated conservatively, or with additional study stent implantation, according 
to the decision of the operator. Also similarly, haziness, lucency or filling defects 
within or adjacent to the stent, could be treated according to the decision of the 
operator.  
 
4.5  Post-procedure Management 
After intervention, a complete neurological exam, including NIH Stroke Scale, was 
performed by an independent neurologist prior to hospital discharge. 
 
A post-procedure perfusion/diffusion CT scan or MRI was done within 7 days. (the 
same diagnostic test that was done at baseline was requested at pre-discharge).  
 
A repeat carotid artery duplex scan before discharge was performed to assess stent 
patency. Clopidogrel 75mg was to be given p.o. once daily for a minimum of 1 month 
after the study procedure. In case of allergy or intolerance to clopidogrel, ticlopidine   - 26 -
250mg p.o. twice daily could be given instead. Aspirin ≥ 100 mg p.o. was to be given 
once daily for a minimum of 6 months. 
 
Post stent implantation, all enrolled patients had to attend 1- month (30 days +/- 10 
days) and 6- month (180 +/- 30 days) clinic visits for the following:  
•Assessment of the patient's clinical status and documentation of any complications,  
• review of anti-coagulation/antiplatelet medications,  
•carotid artery duplex scan to assess stent patency,  
•complete neurological exam, including NIH Stroke Scale, by an independent 
neurologist. 
 
If the patient experienced new or recurrent neurological symptoms, a more detailed 
examination and/or testing could be done according to the investigator’s discretion. If 
the patient had a change in the neurological exam score, or a neurological event was 
suspected, a repeat diffusion/perfusion CT scan or MRI was done.  
 
4.6  Description of Stent 
The Protégé GPS Stent (ev3, Inc) is a new self-expanding Nitinol stent system (Figure 
5 and 6). The stent is laser-cut from a Nitinol tube in an open lattice design. The stent 
is made of a nickel titanium alloy (Nitinol) and comes pre-mounted on a 6 Fr (6-9 mm 
stent) or 7 Fr (10 mm stent), over-the-wire delivery system. The 6 Fr delivery system 
accepts a 0.018" wire, the 7 Fr delivery system a 0.035" wire. Upon deployment, the 
stent achieves its predetermined diameter and exerts a constant, radial force to 
establish and maintain patency. 
 
The delivery system is comprised of an inner and outer sheath, which are locked 
together with a safety lock. The nylon inner shaft terminates distally in a flexible   - 27 -
catheter tip and originates proximally at the hub. Two radiopaque markers, one marker 
distal and one marker/retainer proximal to the constrained stent are on the inner sheath. 
 
The outer sheath connects proximally to the Y-adapter. The self-expanding stent is 
constrained within the space between the inner and outer sheaths. The outer sheath has 
a radiopaque marker at its distal end. 
 
The stent technology utilizes a new stent release system (Figure 7), relying on the 
proximal marker band to serve as a retaining ring. The marker band is cut like an 
interlocking piece to a jigsaw puzzle to interlock with the rounded radiopaque markers 
(Figure 8) at the end of the stent. This system ensures that the stent is held in place 
until the stent is fully released to prevent the stent from jumping forward during 
deployment. The stent size is selected so the diameter is approximately 1mm greater 
than the largest reference diameter. The Protégé GPS stent measurements are shown in 
figure 9. 
 
The Protégé GPS stent offers the unique possibility to inject contrast through the 
stentdelivery system (Starport system) at the exact target lesion spot. This allows 
perfect visualization of the lesion to treat prior to stenting and eliminates eventual 
contrast injection problems encountered by injecting through the long introducer 
sheath. 
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Figure 5: Protégé GPS Stent - Straight Version 
                   
  
 
     
Figure 6: Protégé GPS Stent - Tapered Version 
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Figure 7: Stent Release System 
 
 
Figure 8: Rounded Radiopaque Markers 
 
Outer Sheath 
Safety Lock System   - 30 -
 
Figure 9: Protégé Stent Measurements 
 
4.7  Description of Filters Used in the Trial 
The two filters used in this study were the Spider filter from ev3 (Figure 10) and the 
Filterwire from Boston Scientific (Figure 11). In the majority of cases (75/77, 97%) 
the Spider System was used. This percutaneously delivered distal embolic protection 
device designed to capture and remove debris from internal carotid artery vessels 
during interventional procedures. It allows use of any guidewire to cross the lesion. It 
consists of a capture wire, delivery catheter, stylet, and recovery catheter. The capture 
wire is a Nitinol mesh filter mounted on a convertible 175/320 cm coated 0.014 inch 
stainless steel wire. The recovery catheter is used to recover the filter and capture 
debris. The device is available in five filter sizes: 3, 4, 5, 6 & 7mm.  
 
Unconstrained Stent 
Diameter (mm)  Stent Length (mm)  Configuration 
Lumen 
Diameter (mm) 
6  20, 30, 40, 60  straight 4.5-5.5 
7  20, 30, 40, 60  straight 5.5-6.5 
8  20, 30, 40, 60  straight 6.5-7.5 
9  20, 30, 40, 60  straight 7.5-8.5 
10  20, 30, 40, 60  straight 8.5-9.5 
8-6 30,  40  tapered  (6.5-7.5)-(4.5-
5.5) 
10-7 30,  40  tapered  (8.5-9.5)-(5.5-
6.5)   - 31 -
The Filterwire was used in 2 cases (2/77, 2,6%).It consist of a 0.014” guide wire with a 
shapeable distal tip and a polyurethane filter basket based on an eccentric nitinol loop. 
Due to its expandable loop structure, one size can be placed in vessels between 3.5 and 
5.5 mm in diameter. 
 
 
 
Figure 10: Spider Filter (ev3) 
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Figure 11: Filterwire (Boston Scientific)  
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5  RESULTS 
5.1  Patient Characteristics 
A total of 77 patients were included in this analysis (31 symptomatic, 46 
asymptomatic). Figure 12 shows the patients’ baseline characteristics. The patients’ 
overall mean age was 72 years; they ranged in age from 55 to 87 years. The majority 
(71%) were male. A total of 31 (40%) patients were either current (10 patients, 13%) 
or previous (21 patients, 27%) smokers. Fifteen (20%) patients had been previously 
diagnosed with diabetes. A total of ten (13%) patients had previously had a CEA;  four 
patients (5%) had ipsilateral CEA, while six patients (8%) had contralateral CEA. 
Overall, 43 (56%) patients had at least one co-morbidity or experienced surgery within 
the last five years prior to study enrollment. A summary of the patients’ neurological 
history is shown in figure 13. 
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Figure 12: Patient Characteristics 
 
Baseline Characteristics  (N = 77) 
Age (yr)    
 Mean  ± SD  72 ± 8 
 Median  73 
Gender    
 Male  55  (71%) 
 Female  22  (29%) 
Canadian Cardiac Society (CCS) angina 
class 
 
  None (0)  65 (84%) 
 1  4  (5%) 
 2  2  (3%) 
 3  0  (0%) 
 4  1  (1%) 
     Unknown  5 (7%) 
Smoking 31  (40%) 
     Current  10 (13%) 
     Previous  21 (27%) 
Congestive heart failure  7 (9%) 
Prior MI(s)  12 (16%) 
Other cardiac conditions  28 (36%) 
Hypertension requiring treatment  69 (90%)   - 35 -
Baseline Characteristics  (N = 77) 
Diabetes   15 (20%) 
GI bleeding / active ulcers  1 (1%) 
Ipsilateral endarterectomy  4 (5%) 
Contralateral endarterectomy  6 (8%) 
Current carotid bruits  51 (66%) 
Within last 5 years – total  43 (56%) 
Renal disease or surgery  5 (7%) 
Gastrointestinal disease or surgery  15 (20%) 
Respiratory disease or surgery  10 (13%) 
Musculoskeletal disease or surgery  9 (12%) 
Other disease or surgery  28 (36%) 
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Figure 13: Neurological History 
 
Neurological History  (N = 77) 
Ophthalmic artery ischemia  5 (7%) 
Anterior cerebral artery ischemia  2 (3%) 
Middle cerebral artery ischemia  11 (14%) 
Lacunar ischemia  5 (7%) 
TIA 28  (36%) 
Ischemic stroke  11 (14%) 
 
5.2  Technical Success 
In 75 patients (97%) the procedure was performed with the Spider Filter and in two 
cases a FilterWire (Boston Scientific) was used. Figure 14 displays an example of the 
use of a Spider Filter and a Protégé stent in a left internal carotid artery. There were no 
instances of multiple filter systems being placed. The filter system was successfully 
retrieved in 76 (99%) patients. In one patient, the Spider filter could not be retrieved 
successfully because it got hooked to the distal stent edge. This caused a blockage in 
the cranial part of the stent. The stent was dislodged into the common carotid artery 
and the patient was sent to surgery.  
 
Pre-dilatation of the stenosis was performed in 23 (30%) patients. The stent used in the 
first stent placement was implanted in all 77 patients (100%). There were no 
occurrences of a second stent placement. The stent position was placed postioned 
correcly in all 77 patients (100%). 
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At baseline, 70 patients (91%) had a percent stenosis greater than 80%. The smallest 
percent stenosis was 70% and the greatest percent stenosis was 99%. The minimum 
and maximum percent stenosis after pre-dilatation were 10% and 85%, respectively. 
 
The final outcome percent residual stenosis was 0% for 50 (65%) patients, between 
1% and 10% for 18 (23%) patients, and between 11% and 20% for eight (10%) 
patients. Of the 77 patients included in this analysis, 76 (99%) patients met the criteria 
for technical success, with a residual stenosis of less than 30%. 
 
Figure 14: Angiographic Images of Intervention 
 
 
5.3  Patient Outcomes at One Month 
During the first month after the procedure, the primary endpoint of the study was 
observed in four patients (all symptomatic), giving an overall incidence rate of 5.2% 
(95% C.I. 0.2% – 10.2%). There were three MANEs which were ipsilateral major 
strokes (incidence rate = 3.9%, 95% C.I. 0.0% – 8.2%) and one ipsilateral minor 
stroke (incidence rate = 1.3%, 95% C.I. = 0.0%-3.8%). During the procedure, one   - 38 -
major stroke occurred and was adjudicated by the CEC to be procedure- related; the 
second major stroke occurred two days after the procedure, and was adjudicated to be 
related to both the device and the procedure; the third major stroke occurred 31 days 
after the procedure and was adjudicated by the CEC to be unrelated to the device or 
procedure. The minor stroke occurred on the day of the procedure and was adjudicated 
to be procedure-related. There were no deaths between enrollment and the one-month 
follow-up visit.   
 
At the 1 month follow up, seventy four patients had a duplex scan. This could be 
evaluated in 67 of these patients (one patient had been excluded from the analysis as 
the stent was removed during an endarterectomy immediately post procedure). No 
restenosis was seen in 60 patients (89.6%) at 1 month follow up. Only two patients 
(3.0%) had a mild stenosis (stenosis < 50%). Minimal stenosis (stenosis < 30%) was 
detected in five patients (7.5%).  
 
5.4  Patient Outcomes at Six Months 
An additional MANE occurred between the one month and six month follow-up visit 
in a patient with an asymptomatic lesion (the patient had a symptomatic contralateral 
lesion with an ischemic stroke four years prior to the procedure) who had a 
contralateral major stroke 75 days after the procedure. The stroke type was ischaemic 
and located in the occipital cerebral cortex. The probable source was the vertebral 
artery. The patient died 36 days later. Thus, five patients in total experienced a MANE 
by the six -month follow-up visit, giving an overall incidence rate of 6.5% (95% C.I. 
1.0% - 12.0%). An additional death occurred on post-procedure day 151. The patient 
had a history of myocardial infarction, hyperuricaemia, homocysteinaemia and 
polyglobulinaemia. At the 1 month follow up visit, the aspirin treatment had been 
stopped as the patient had been admitted for a CAGB. The patient had a major 
ischaemic stroke (assumed cardiac origin) located in the frontal cerebral cortex while   - 39 -
in hospital for a CABG, unrelated to the procedure or the study device. The patient 
developed a sepsis related to recurrent urinary tract infections and died.   
 
Out of 72 patients, 66 (92%) had a carotid duplex scan for the 6 -month follow up 
visit. One patient had been excluded from the analysis as the stent had been removed 
during the CEA immediately post-procedure. There was no restenosis seen in 51 
patients (77.3%). Twelve patients (18.2%) had minimal stenosis (stenosis < 30%) 
while three patients (4.5%) had a mild stenosis (stenosis < 50%).  
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6  DISCUSSION 
 
Carotid stenting has become an important alternative to CEA. Currently, it is routinely 
performed in many centers with increasing numbers of patients seeking a less invasive 
treatment alternative. The introduction of distal embolic protection devices and 
sophisticated stent designs, and increased operator experience have improved the 
outcome of carotid artery stenting [28, 29, 30, 31]. 
 
6.1 Surgical  Trials 
Two large trials, the North American Symptomatic Endarterectomy Trial (NASCET) 
and the European Carotid Surgery Trial (ECST) have effectively shown that carotid 
endarterectomy can prevent strokes and death in symptomatic patients compared to 
best medical therapy [18, 19, 20]. Shortly after these trials were published, carotid 
endarterectomy was considered the gold standard for treatment of carotid stenosis. 
 
In the NASCET trial, patients with symptomatic internal carotid artery stenosis of 
more than 70% were randomized to receive either carotid endarterectomy or medical 
therapy. The cumulative risk of ipsilateral stroke was 9% for the surgical group and 
26% for the medical group. This was an absolute reduction of 17%. The risk of 
ipsilateral stroke was also significantly reduced (p= 0.045) in patients with a carotid 
stenosis of 50-69% who received endarterectomy. 
 
In the ECST trial, the risk of any death or stroke after 3 years was 12.3% for patients 
with a stenosis greater than 80% in the surgical group and 21.9% in the group of 
patients treated with medical therapy only. This lead to a significant benefit of 11.6% 
after 3 years.
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The Asymptomatic carotid Artherosclerosis Study (ACAS) and the Asymptomatic 
Carotid Surgery Trial (ACST) trials have shown that endarterectomy is also beneficial 
in asymptomatic carotid stenoses [32, 33]. .  
 
In the ACAS trial, patients with an asymptomatic carotid stenosis of more than 60% 
were included. The trial did not reveal any benefit of surgery in preventing major 
stroke during follow-up (stroke rate 3.4% vs 6.02% in medical group, N.S.). However, 
by considering minor and major strokes together, a beneficial effect of carotid 
endarterectomy could be evidenced (5.9% stroke reduction at 5 years: 5.1% ipsilateral 
stroke at 5 years after surgery vs 11% stroke at 5 years under medical treatment) [32].   
 
The 5-year-results of the ACST Trial have shown an absolute risk reduction of major 
stroke at 5 years of 2.5% for patients aged under 75 years with asymptomatic carotid 
stenoses of 70% or more in duplex ultrasound [33].  
 
6.2  Clinical Series of Carotid Stenting 
A summary of carotid stenting results, containing the data of 12.392 procedures 
involving 11.243 patients from 53 centers, was published in 2003 by Wholey et al 
[34]. The incidence of complications occurring during the 30 days post implant were: 
TIAs (3.1%), minor strokes (2.1%), major strokes (1.2%), death (0.6%).  
 
In 2001 Roubin et al. reported a series of 528 consecutive patients undergoing carotid 
stenting [35]. The major stroke rate was 1% (n=6) and the minor stroke rate was 4.8% 
(n=29). The overall stroke and death rate within 30 days was 7.4%. 
 
In 2003 Cremonesi et al published a series of 442 consecutive patients treated with 
carotid stenting under embolic protection [36]. 1.1% of the patients experienced either 
a stroke or death within 30 days.   - 42 -
The German Society of Angiology and Radiology developed a prospective register for 
Carotid stenting. The results of the first 48 months from a total of 38 participating 
centers were published in 2004 [37]. A total of 3267 patients who suffered from 
cartotid stenosis were treated by stent implantation. The procedure was successful in 
98% of all interventions. The perioperative death rate was 0.6%, the major stroke rate 
was 1.2% and the rate of minor stroke was 1,3%. 
 
Bosiers et al. published the ELOCAS registry in 2005 which retrospectively and 
prospectively collected data from four so-called “high-volume” Carotid stenting 
centers [38]. A total of 2172 patients were consecutively treated, 99.7% of the 
procedures were technically successful. The stroke/death rate was 4.1% after one year, 
10.1% after three years, and 15.5% after five year follow-up. 
 
The CAPTURE (Carotid Acculink/Accunet Post-Approval Trial to Uncover 
Unanticipated or Rare Events) registry was published in 2007 [39]. In this registry, 
3500 patients who were considered to be of high operative risk and had a Carotid 
stenosis >50% (symptomatic) or >80% asymptomatic were included. The 
stroke/death/myocardial infarction rate was 6.3% after 30 days. The major stroke/death 
rate after 30 days was 2.9%. 
 
The ARCHeR study was published by Gray et al in 2006 [40]. The study was designed 
as a three part multicenter study. In ARCHeR 1 the use of Acculink (Guidant) Carotid 
stents were evaluated. The following two studies (ARCHeR 2 and 3) also evaluated 
the adjuvant use of the Accunet (Guidant) embolic protection device. In total, 581 
patients with high operative risk were included in 48 centers between the year 2000 
and 2003. The combined primary endpoint of stroke/death/myocardial infarction was 
8.3% after 30 days. The rate of ipsilateral stroke between the first month up to one 
year was 1.8%.The rate of restenosis was 2.2% up to one year follow up. 
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The CaRESS trial was a non-randomized, multicenter trial. It included 143 patients 
who were treated by Carotid stenting and 254 patients who were treated by Carotid 
Endarterectomy. No significant difference concerning the rate of stroke or death was 
detected after 30 days (2.1% stent, 3.6% surgery) or after one year follow up (10.0% 
stent, 13.6% surgery) [41]. 
 
6.3  Randomized Trials  
The Carotid and Vertebral Transluminal Angioplasty Study (CAVATAS) was the first 
large study, in which carotid angioplasty was compared to CEA [23]. The incidence of 
MANEs was 10% in both the carotid angioplasty and carotid endarterectomy groups.  
 
The SAPPHIRE study compared carotid stenting with carotid endarterectomy using a 
randomized study design but also a registry study [24]. The incidence of MANEs was 
4.5% for the stented patients and 6.6% for the CEA patients in the randomized study; 
this study enrolled high risk patients for carotid endarterectomy. In the registry study, 
where all patients could be entered, the incidence of MANEs was 6.9% in the stented 
patients.  
 
The EVA-3S compared carotid stenting to endarterectomy in patients with a 
symptomatic carotid stenosis of at least 60% [42]. The entrance criteria for 
participating interventionalists were was set very low. A participating inteventionalist 
was required to have performed only 12 prior carotid stenting procedures. The 30-day 
incidence of stroke or death was lower in the group of patients in whom the procedure 
was performed under embolic protection compared to those patients in whom carotid 
stenting was performed without embolic protection (18/227, 7.9% versus 5/20, 25% 
respectively, p=0.03). For this reason the stenting arm of the trial without the use of an 
embolic protection device was stopped prematurely by the safety committee. The 30-
day risk of any stroke or death was significantly higher after stenting (9.6%) than after 
endarterectomy (3.9%) which resulted in a relative risk of 2.5.   - 44 -
 
In the Stent-protected Percutaneous Angioplasty of the Carotid versus Endarterectomy 
trial (SPACE), patients with symptomatic carotid stenosis of more than 70% in duplex 
ultrasound or over 50% according to NASCET measurement were included [43]. The 
use of embolic protection was optional. Many interventional centers had problems 
fulfilling the entrance criteria (more than 25 carotid stent procedures previously 
performed), which meant many centers had only very limited experience in this 
procedure. The rate of death or ipsilateral ischemic stroke was 6.84% in the group of 
patients treated with stent implantation compared to 6.34% in the group of patients 
treated with endarterectomy. Although embolic protection devices have become 
standard in most centers around the world, 73% of all interventions were performed 
without them. Complications such as myocardial infarction, contralateral stroke, or 
cranial nerve palsy — some of them more common to or only occurring during surgery 
— were not considered by the study. The trial was a noninferiority rather than a 
superiority trial, with a noninferiority margin defined as less than 2.5%, based on an 
event rate of 5% - the one-sided p-value for non-inferiority was 0.09. The trial was 
halted prematurely due to low recruitment and lack of further funding after including 
only 1200 patients, while the analysis of more than 2500 patients would have been 
necessary in order to reach a statistical power of merely 80%. According to the 
investigators of the trial, the results failed to prove non-inferiority of carotid stenting 
compared to endarterectomy. 
 
Overviewing all major randomized trials so far, the differences between surgery and 
stenting have been very small. 
 
The CREST Trial (Carotid Revascularization Endarterectomy vs. Stenting Trial) has 
been recruiting patients since the year 2000. Preliminary results of the lead-in phase of 
the interventional part of the trial have been published in 2004. So far, the data shows 
a significantly higher risk of periprocedural complications with older age. The 
stroke/death rate in the patient cohort younger than 60 years was 1.6%, in the group of   - 45 -
patients between 60-69 years 1,3%, between 70-79 years of age 5,3% and 12,1% in 
patients 80 years of age or older. The significant results were independent of the 
patients´neurological status, grade of stenosis or the use of embolic protection systems 
[44]. 
 
 
Recently, the ICSS (International Carotid Stenting Study) and ACT 1 Trial 
(Asymptomatic Carotid Stenosis, Stenting Versus Endarterectomy Trial) have begun 
recruitment of eligible patients. Two other large randomized trials, the TACIT 
(Transatlantic Asymptomatic Carotid Intervention Trial) and ACST-2 trial 
(Asymptomatic Carotid Surgery Trial 2) have not yet begun recruiting. Their results 
may lead to new perspectives on the treatment success of asymptomatic lesions, such 
as on the benefit to patients´neurokognitive function. 
 
6.4  Clinical Trials With Use of the Protégé Stent 
The first study using the Protégé stent with the Spider embolic protection filter in high-
risk patients was the CREATE feasibility trial [45]. High-risk features included age > 
75 years, left ventricular ejection fraction < 35%, and restenosis after prior carotid 
endarterectomy.  Procedural success was 100%. Thirty patients were included in the 
trial. In-hospital complications included severe vasovagal reactions in six patients 
(20%) and a popliteal embolus in one patient (3.3%), treated by successful 
embolectomy. During the first 30 days of follow up, two patients (6.6%) experienced 
minor neurological deficits, including transient expressive aphasia that resolved 
without therapy in one patient and homonymous hemianopsia due to contralateral 
posterior circulation stroke in one patient. Therefore, MANE rate was 6.6% at one 
month.  
 
Between April 2004 and October 2004 a prospective non-randomized multicenter 
registry of 419 patients with severe carotid stenosis and high-risk features for carotid   - 46 -
endarterectomy was performed [46]. Carotid artery stenting was solely performed with 
the Protégé Stent and the Spider Embolic Protection System (ev3). The primary 
outcome was the combined incidence of major adverse cardiac and cerebrovascular 
events at 30 days after intervention, including death, stroke, and myocardial infarction. 
A secondary outcome was the technical success, defined as successful deployment of 
all devices, filter retrieval, and final diameter stenosis <50%. Technical success was 
achieved in 408 of 419 patients (97.4%). The primary end point was observed in 26 
patients (6.2%), including death in 8 (1.9%), nonfatal stroke in 14 (3.3%), and nonfatal 
myocardial infarction in 4 (1%). Independent predictors of death or stroke at 30 days 
included duration of filter deployment, symptomatic carotid stenosis, and baseline 
renal insufficiency. 
 
In the PROCAR study, four MANEs occurred from the procedure to the 1 month 
follow up. One major stroke occurred between the 1 month visit and the 6 month visit 
and was not related to either the device or the procedure. This patient died following 
the stroke. The incidence of MANEs at 1 month of 5.2% and 6.5% at 6 months  in this 
study is comparable to what has been reported in other carotid stenting studies.  
 
The PROCAR trial, as well as the CREATE feasibility trial and CREATE registry 
have shown a high technical success rate, with a high rate of correct placement of the 
stent in particular. 
 
The PROCAR trial was designed to evaluate the safety and performance of the Protégé 
Stent in the treatment of common and/or internal carotid artery stenosis with 
adjunctive use of a filter embolic protection device. Investigators were free to choose 
any distal embolic protection device. Although it was not an objective of the study, 
this result suggests a good match between the Protégé stent and the Spider filter 
device.   - 47 -
7  CONCLUSION 
 
In conclusion, the use of the new Protégé Stent with a new stent release system in 
combination with an embolic protection device satisfies safety and performance 
criteria for the treatment of carotid artery stenosis and presents an acceptable risk to 
patients with an incidence of MANEs similar to other carotid stent and endarterectomy 
trials.   - 48 -
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ESCT European  Carotid  Surgery Trialists' Collaborative Group 
Fr French  Catheter  Scale:  3 French = 0.039 inch = 1 mm 
MANE   Major Adverse Neurological Event   
MI Myocardial  Infarction   
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